350 related articles for article (PubMed ID: 16800964)
21. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.
Fiala O; Pesek M; Finek J; Racek J; Minarik M; Benesova L; Bortlicek Z; Sorejs O; Kucera R; Topolcan O
Neoplasma; 2016; 63(3):471-6. PubMed ID: 26952513
[TBL] [Abstract][Full Text] [Related]
22. Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.
Fu P; Pennell NA; Sharma N; Yi Q; Dowlati A
Rev Recent Clin Trials; 2017; 12(1):51-58. PubMed ID: 27633965
[TBL] [Abstract][Full Text] [Related]
23. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
24. Erlotinib: as maintenance monotherapy in non-small-cell lung cancer.
Muir VJ; Dhillon S
BioDrugs; 2011 Jun; 25(3):139-46. PubMed ID: 21513367
[TBL] [Abstract][Full Text] [Related]
25. FDA drug approval summary: erlotinib (Tarceva) tablets.
Cohen MH; Johnson JR; Chen YF; Sridhara R; Pazdur R
Oncologist; 2005 Aug; 10(7):461-6. PubMed ID: 16079312
[TBL] [Abstract][Full Text] [Related]
26. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
[TBL] [Abstract][Full Text] [Related]
27. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
Zugazagoitia J; Puente J; González-Larriba JL; Manzano A; Sotelo M; Hernández S; Sanz J; Pérez P; Díaz-Rubio E
Oncology; 2013; 84(5):255-64. PubMed ID: 23428780
[TBL] [Abstract][Full Text] [Related]
28. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
29. Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Nishinarita N; Igawa S; Kasajima M; Kusuhara S; Harada S; Okuma Y; Sugita K; Ozawa T; Fukui T; Mitsufuji H; Yokoba M; Katagiri M; Kubota M; Sasaki J; Naoki K
Oncology; 2018; 95(2):109-115. PubMed ID: 29698957
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Lee CK; Davies L; Wu YL; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu YK; Gralla RJ; Gebski V; Mok T; Yang JC
J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376144
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
[TBL] [Abstract][Full Text] [Related]
32. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.
Aydiner A; Yildiz I; Seyidova A
Asian Pac J Cancer Prev; 2013; 14(5):3255-61. PubMed ID: 23803112
[TBL] [Abstract][Full Text] [Related]
34. "Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".
Hann CL; Brahmer JR
Curr Treat Options Oncol; 2007 Feb; 8(1):28-37. PubMed ID: 17634830
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Gregorc V; Novello S; Lazzari C; Barni S; Aieta M; Mencoboni M; Grossi F; De Pas T; de Marinis F; Bearz A; Floriani I; Torri V; Bulotta A; Cattaneo A; Grigorieva J; Tsypin M; Roder J; Doglioni C; Levra MG; Petrelli F; Foti S; Viganò M; Bachi A; Roder H
Lancet Oncol; 2014 Jun; 15(7):713-21. PubMed ID: 24831979
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
Carbone DP; Ding K; Roder H; Grigorieva J; Roder J; Tsao MS; Seymour L; Shepherd FA
J Thorac Oncol; 2012 Nov; 7(11):1653-60. PubMed ID: 23059783
[TBL] [Abstract][Full Text] [Related]
37. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
38. Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial.
Rossi D; Dennetta D; Ugolini M; Catalano V; Alessandroni P; Giordani P; Baldelli AM; Casadei V; Graziano F; Luzi Fedeli S
Target Oncol; 2010 Dec; 5(4):231-5. PubMed ID: 20890670
[TBL] [Abstract][Full Text] [Related]
39. [Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Tang CH; Liu XQ; Gao HJ; Li JJ; Guo WF; Li XY; Wang WX; Liu B; Qu LL; Wang WW
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):143-7. PubMed ID: 20403247
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
